• KemPharm Receives of Two Additional U.S. Patents americanpharmaceuticalreview
    August 04, 2020
    KemPharm announced the United States Patent and Trademark Office (USPTO) has recently issued two new patents to KemPharm governing methods of use and composition of matter for methylphenidate-based prodrugs.
  • KemPharm Submits KP415 NDA to FDA for ADHD americanpharmaceuticalreview
    March 04, 2020
    KemPharm has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for its investigational product candidate, KP415, to the U.S. Food and Drug Administration (FDA).
PharmaSources Customer Service